Tag: anastrozoleArimidex

Articles

• Aromatase inhibitor treatment and weight gain
• Foods to eat & avoid during aromatase inhibitor treatment
• Impact of endocrine therapy (hormone therapy) on BC prognosis

News

04/30/13

Side effects of anti-estrogens can indicate treatment is working

07/19/12

Aromatase inhibitors are less effective in women with high BMI

07/17/11

Increasing aromatase inhibitor side effects make tamoxifen attractive

11/18/10

Aromatase inhibitors have many potential side effects

Studies

• Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial Cite
  Cuzick J, Chu K, Keevil B, Brentnall AR, Howell A, Zdenkowski N, et al. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial. The Lancet Oncology. Elsevier BV; 2023; 10.1016/s1470-2045(23)00578-8
• The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer Cite
  Lammers SWM, Geurts SME, Van Hellemond IEG, Swinkels ACP, Smorenburg CH, Van Der Sangen MJC, et al. The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer. JNCI Cancer Spectrum. Oxford University Press (OUP); 2023; 10.1093/jncics/pkad092
• In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment Cite
  Bezerra PHA, Amaral C, Almeida CF, Correia-da-Silva G, Torqueti MR, Teixeira N. In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment. Molecules. MDPI AG; 2023; 28:4893 10.3390/molecules28134893
• Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial Cite
  Iwase T, Saji S, Iijima K, Higaki K, Ohtani S, Sato Y, et al. Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 10.1200/jco.22.00577
• Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail Cite
  Arnachellen D, Xulu KR, Pillay K, Augustine TN. Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail. Microscopy and Microanalysis. Oxford University Press (OUP); 2023; 10.1093/micmic/ozad032
• Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials Cite
  Bradley R, Braybrooke J, Gray R, Hills RK, Liu Z, Pan H, et al. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet Oncology. Elsevier BV; 2022; 10.1016/s1470-2045(21)00758-0
• Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions Cite
  Harrigan M, McGowan C, Hood A, Ferrucci LM, Nguyen T, Cartmel B, et al. Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions. Nutrients. MDPI AG; 2021; 13:3730 10.3390/nu13113730
• Vitamin D Compounds PRI-2191 and PRI-2205 Enhance Anastrozole Activity in Human Breast Cancer Models Cite
  Filip-Psurska B, Psurski M, Anisiewicz A, Libako P, Zbrojewicz E, Maciejewska M, et al. Vitamin D Compounds PRI-2191 and PRI-2205 Enhance Anastrozole Activity in Human Breast Cancer Models. International Journal of Molecular Sciences. MDPI AG; 2021; 22:2781 10.3390/ijms22052781
• Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ Cite
  Sestak I, Cuzick J, Bonanni B, Bundred N, Levy C, Loib S, et al. Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ. General Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-gs2-02
• Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial Cite
  Sestak I, Blake G, Patel R, Cuzick J, Howell A, Coleman R, et al. Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. British Journal of Cancer. Springer Science and Business Media LLC; 2021; 10.1038/s41416-020-01228-2
• Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial Cite
  Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2020; 21:1443-1454 10.1016/s1470-2045(20)30458-7
• Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α Cite
  Ingle JN, Cairns J, Suman VJ, Shepherd LE, Fasching PA, Hoskin TL, et al. Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α. Clinical Cancer Research. American Association for Cancer Research (AACR); 2020; 26:2986-2996 10.1158/1078-0432.ccr-19-3091
• Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial Cite
  Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. The Lancet. Elsevier BV; 2020; 395:117-122 10.1016/s0140-6736(19)32955-1
• Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer Cite
  Li L, Chang B, Jiang X, Fan X, Li Y, Li T, et al. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4878-4
• Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27 Cite
  Strasser-Weippl K, Higgins MJ, Chapman JW, Ingle JN, Sledge GW, Budd GT, et al. Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2018; 110:1003-1008 10.1093/jnci/djy017
• Tualang honey adjunct with anastrozole improve parenchyma enhancement of breast tissue in breast cancer patients: A randomized controlled trial Cite
  Hizan NS, Hassan NHM, Haron J, Abubakar MB, Mahdi NMN, Gan SH. Tualang honey adjunct with anastrozole improve parenchyma enhancement of breast tissue in breast cancer patients: A randomized controlled trial. Integrative Medicine Research. Elsevier BV; 2018; 7:322-327 10.1016/j.imr.2018.07.002
• Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27 Cite
  Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd L, O'Shaughnessy J, Parulekar W, et al. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. European Journal of Cancer. Elsevier BV; 2018; 90:19-25 10.1016/j.ejca.2017.11.014
• Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial Cite
  Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet. Elsevier BV; 2016; 388:2997-3005 10.1016/s0140-6736(16)32389-3
• Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) Cite
  Shapiro AC, Adlis SA, Robien K, Kirstein MN, Liang S, Richter SA, et al. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:501-512 10.1007/s10549-016-3710-6
• Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial Cite
  Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. The Lancet. Elsevier BV; 2016; 387:849-856 10.1016/s0140-6736(15)01168-x
• Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial Cite
  Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J. Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:139-143 10.1200/jco.2015.63.4972
• New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane Cite
  HOLE S, PEDERSEN AM, HANSEN SK, LUNDQVIST J, YDE CW, LYKKESFELDT AE. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. International Journal of Oncology. Spandidos Publications; 2015; 46:1481-1490 10.3892/ijo.2015.2850
• Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial Cite
  Stearns V, Chapman JW, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, et al. Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:265-271 10.1200/jco.2014.57.6926
• Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells Cite
  Ismail AM, In LL, Tasyriq M, Syamsir DR, Awang K, Omer Mustafa AH, et al. Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells. Food and Chemical Toxicology. Elsevier BV; 2013; 62:817-824 10.1016/j.fct.2013.10.024
• Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer Cite
  Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M. Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:2977-2980 10.1200/jco.2012.42.0273
• Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer Cite
  Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 134:727-734 10.1007/s10549-012-2085-6
• Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group Cite
  Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, et al. Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:722-728 10.1200/jco.2011.36.8993
• Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole Cite
  Singh S, Cuzick J, Mesher D, Richmond B, Howell A. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 132:625-629 10.1007/s10549-011-1911-6
• Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial. Cite
  Pfeiler G, Königsberg R, Mlineritsch B, Stoger H, Singer CF, Poestlberger S, et al. Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:514-514 10.1200/jco.2011.29.15_suppl.514
• Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis Cite
  Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1299-1309 10.1093/jnci/djr242
• Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer Cite
  Edwards BJ, Raisch DW, Shankaran V, McKoy JM, Gradishar W, Bunta AD, et al. Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer. Clinical Cancer Research. American Association for Cancer Research (AACR); 2011; 17:560-568 10.1158/1078-0432.ccr-10-1595
• Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial Cite
  Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:3411-3415 10.1200/jco.2009.27.2021
• Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women Cite
  Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'Hern R, Crowder RJ, et al. Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1161-1167 10.1200/jco.2009.23.9616
• Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study Cite
  Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 120:127-134 10.1007/s10549-009-0692-7